- Home
- Publications
- Publication Search
- Publication Details
Title
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 10, Pages 2111
Publisher
MDPI AG
Online
2017-10-09
DOI
10.3390/ijms18102111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF
- (2017) Jiyeon Choi et al. NATURE GENETICS
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
- (2017) LE Dockery et al. OncoTargets and Therapy
- Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach
- (2017) Salete J. Baptista et al. PLoS One
- A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation
- (2016) J.K. Litton et al. ANNALS OF ONCOLOGY
- PARP inhibitors in ovarian cancer
- (2016) J. A. Ledermann ANNALS OF ONCOLOGY
- PARP inhibitors: the race is on
- (2016) Jessica S Brown et al. BRITISH JOURNAL OF CANCER
- Design, Synthesis, and Biological Evaluation of Some Cyclohepta[b]Thiophene and Substituted Pentahydrocycloheptathieno[2,3-d]Pyrimidine Derivatives
- (2016) Elshaymaa I. Elmongy et al. JOURNAL OF HETEROCYCLIC CHEMISTRY
- Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors
- (2016) Monica E. Wielgos et al. MOLECULAR CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair
- (2016) E-B Choi et al. ONCOGENE
- DNA repair targeted therapy: The past or future of cancer treatment?
- (2016) Navnath S. Gavande et al. PHARMACOLOGY & THERAPEUTICS
- Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation
- (2016) B. A. Gibson et al. SCIENCE
- PARP-1 may be involved in angiogenesis in epithelial ovarian cancer
- (2016) Wei Wei et al. Oncology Letters
- Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
- (2016) Florian Engert et al. Oncotarget
- Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer
- (2016) Leilei Fu et al. Scientific Reports
- Functions of PARylation in DNA Damage Repair Pathways
- (2016) Huiting Wei et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres
- (2015) Torun Ekblad et al. Chemical Biology & Drug Design
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib
- (2015) K. Lin et al. EUROPEAN JOURNAL OF CANCER
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
- (2015) Felix Y. Feng et al. MOLECULAR CELL
- Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
- (2015) Sebastian Eustermann et al. MOLECULAR CELL
- Nuclear PARP1 expression and its prognostic significance in breast cancer patients
- (2015) Annalisa Mazzotta et al. TUMOR BIOLOGY
- Profile of veliparib and its potential in the treatment of solid tumors
- (2015) Lars Wagner OncoTargets and Therapy
- Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
- (2014) Barbara Lupo et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- (2014) M. A. Smith et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
- (2014) K. A. Reiss et al. CLINICAL CANCER RESEARCH
- Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3
- (2014) Carole Beck et al. EXPERIMENTAL CELL RESEARCH
- PARP Inhibitors as P-glyoprotein Substrates
- (2014) Denise Lawlor et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Transcriptional Roles of PARP1 in Cancer
- (2014) Matthew J. Schiewer et al. MOLECULAR CANCER RESEARCH
- Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node-negative early breast cancer: 15-year follow-up
- (2014) PIOTR DONIZY et al. ONCOLOGY REPORTS
- Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
- (2014) Marine Gilabert et al. PLoS One
- Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors
- (2013) Qihua Zhu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer
- (2013) J. D. Steffen et al. CANCER RESEARCH
- PARP expression in germ cell tumours
- (2013) Michal Mego et al. JOURNAL OF CLINICAL PATHOLOGY
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- PARP-1 and gene regulation: Progress and puzzles
- (2013) W. Lee Kraus et al. MOLECULAR ASPECTS OF MEDICINE
- The complexity of NF-κB signaling in inflammation and cancer
- (2013) Bastian Hoesel et al. Molecular Cancer
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
- (2013) M. Ihnen et al. MOLECULAR CANCER THERAPEUTICS
- PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant Transformation
- (2013) María Isabel Rodríguez et al. PLoS Genetics
- PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
- (2013) Amanda Swindall et al. Cancers
- Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
- (2013) Alice N. Weaver et al. Frontiers in Oncology
- HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair
- (2012) S. Nowsheen et al. CANCER RESEARCH
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- PARP-1 protein expression in glioblastoma multiforme
- (2012) A. Galia et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Potential Role of Poly(ADP-Ribose) Polymerase (PARP) Activation in Methotrexate-Induced Nephrotoxicity and Tubular Apoptosis
- (2012) Selvinaz Dalaklioglu et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks
- (2012) Ammar A E Ali et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
- (2012) M.-F. Langelier et al. SCIENCE
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
- (2011) Pawel Domagala et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Structural studies of the PARP-1 BRCT domain
- (2011) Paul A Loeffler et al. BMC STRUCTURAL BIOLOGY
- Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases
- (2010) Daniele Santini et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
- (2009) Gianluca Papeo et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression
- (2009) Rosa Quiles-Perez et al. HEPATOLOGY
- Global Analysis of Transcriptional Regulation by Poly(ADP-ribose) Polymerase-1 and Poly(ADP-ribose) Glycohydrolase in MCF-7 Human Breast Cancer Cells
- (2009) Kristine M. Frizzell et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP1 expression in pediatric central nervous system tumors
- (2009) Valerie N. Barton et al. PEDIATRIC BLOOD & CANCER
- Domain C of Human Poly(ADP-ribose) Polymerase-1 Is Important for Enzyme Activity and Contains a Novel Zinc-Ribbon Motif†,‡
- (2008) Zhihua Tao et al. BIOCHEMISTRY
- Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation
- (2008) W Lee Kraus CURRENT OPINION IN CELL BIOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started